Abeona Therapeutics (NASDAQ:ABEO) Upgraded to Hold at StockNews.com

Abeona Therapeutics (NASDAQ:ABEO) was upgraded by analysts at StockNews.com from a “sell” rating to a “hold” rating in a research report issued on Thursday.

ABEO has been the topic of a number of other research reports. Cantor Fitzgerald reissued an “overweight” rating and set a $18.00 price objective on shares of Abeona Therapeutics in a research report on Tuesday, October 29th. HC Wainwright reaffirmed a “buy” rating and issued a $15.00 price target on shares of Abeona Therapeutics in a research report on Monday.

Abeona Therapeutics Stock Performance

Shares of ABEO opened at $6.41 on Thursday. The company has a current ratio of 6.12, a quick ratio of 6.12 and a debt-to-equity ratio of 0.31. The stock has a market capitalization of $278.64 million, a P/E ratio of -2.38 and a beta of 1.52. The firm’s fifty day simple moving average is $6.22 and its two-hundred day simple moving average is $5.32. Abeona Therapeutics has a 12 month low of $3.05 and a 12 month high of $9.01.

Institutional Investors Weigh In On Abeona Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Geode Capital Management LLC increased its stake in Abeona Therapeutics by 21.7% in the 3rd quarter. Geode Capital Management LLC now owns 465,317 shares of the biopharmaceutical company’s stock valued at $2,942,000 after buying an additional 83,050 shares during the last quarter. XTX Topco Ltd purchased a new stake in Abeona Therapeutics in the 3rd quarter valued at about $160,000. Jane Street Group LLC purchased a new stake in Abeona Therapeutics in the 3rd quarter valued at about $84,000. Western Standard LLC increased its stake in Abeona Therapeutics by 7.0% in the 3rd quarter. Western Standard LLC now owns 1,698,097 shares of the biopharmaceutical company’s stock valued at $10,732,000 after buying an additional 110,998 shares during the last quarter. Finally, Citigroup Inc. increased its stake in Abeona Therapeutics by 10.1% in the 3rd quarter. Citigroup Inc. now owns 616,668 shares of the biopharmaceutical company’s stock valued at $3,897,000 after buying an additional 56,332 shares during the last quarter. Hedge funds and other institutional investors own 80.56% of the company’s stock.

About Abeona Therapeutics

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.